T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes

International Journal of Pharmaceutics

Volumn 392, Issue 1-2, 2010, Pages 218-223

  Koide, Hiroyuki ^a   Asai, Tomohiro ^a   Hatanaka, Kentaro ^a   Akai, Shuji ^a   Ishii, Takayuki ^a   Kenjo, Eriya ^a   Ishida, Tatsuhiro ^b   Kiwada, Hiroshi ^b   Tsukada, Hideo ^c   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Accelerated blood clearance; Liposome; Nanocarriers; Polyethylene glycol; Thymus independent type 2 antigen

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN M ANTIBODY; LIPOSOME; MACROGOL; THYMUS INDEPENDENT ANTIGEN; THYMUS INDEPENDENT ANTIGEN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG DISTRIBUTION; ENCAPSULATION; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; TISSUE DISTRIBUTION;

ANIMALS; ANTIGENS, T-INDEPENDENT; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; IMMUNOGLOBULIN M; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, SCID; POLYETHYLENE GLYCOLS; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 77952741528     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.022     Document Type: Article

References (29)

1. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996, 272:54-60.
2. Allen T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 1994, 15:215-220.
3. Beringue V., Demoy M., Lasmezas C.I., Gouritin B., Weingarten C., Deslys J.P., Andreux J.P., Couvreur P., Dormont D. Role of spleen macrophages in the clearance of scrapie agent early in pathogenesis. J. Pathol. 2000, 190:495-502.
4. Berry G., Billingham M., Alderman E., Richardson P., Torti F., Lum B., Patek A., Martin F.J. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. 1998, 9:711-716.
5. Dams E.T., Laverman P., Oyen W.J., Storm G., Scherphof G.L., Van Der Meer J.W., Corstens F.H., Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000, 292:1071-1079.
6. Garcia De Vinuesa C., O'leary P., Sze D.M., Toellner K.M., Maclennan I.C. T-independent type 2 antigens induce B cell proliferation in multiple splenic sites, but exponential growth is confined to extrafollicular foci. Eur. J. Immunol. 1999, 29:1314-1323.
7. Ishida T., Atobe K., Wang X., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 2006, 115:251-258.
8. Ishida T., Harada M., Wang X.Y., Ichihara M., Irimura K., Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 2005, 105:305-317.
9. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 2006, 115:243-250.
10. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 2006, 112:15-25.
11. Ishida T., Maeda R., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 2003, 88:35-42.
12. Ishida T., Masuda K., Ichikawa T., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm. 2003, 255:167-174.
13. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 2007, 122:349-355.
14. Koide H., Asai T., Hatanaka K., Urakami T., Ishii T., Kenjo E., Nishihara M., Yokoyama M., Ishida T., Kiwada H., Oku N. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm. 2008, 362:197-200.
15. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1991, 1070:187-192.
16. Laverman P., Carstens M.G., Boerman O.C., Dams E.T., Oyen W.J., Van Rooijen N., Corstens F.H., Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther. 2001, 298:607-612.
17. Liu Y.J., Oldfield S., Maclennan I.C. Memory B cells in T cell-dependent antibody responses colonize the splenic marginal zones. Eur. J. Immunol. 1988, 18:355-362.
18. Liu Y.J., Zhang J., Lane P.J., Chan E.Y., Maclennan I.C. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur. J. Immunol. 1991, 21:2951-2962.
19. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
20. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 2004, 100:41-52.
21. Martin F., Kearney J.F. Marginal-zone B cells. Nat. Rev. Immunol. 2002, 2:323-335.
22. Muggia F.M. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res. 1999, 5:7-8.
23. O'brien M., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D., Tomczak P., Ackland S., Orlandi F., Mellars L., Alland L., Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449. Group Caelyx Breast Cancer Study.
24. Oku N., Doi K., Namba Y., Okada S. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int. J. Cancer 1994, 58:415-419.
25. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195:11-20.
26. Urakami T., Akai S., Katayama Y., Harada N., Tsukada H., Oku N. Novel amphiphilic probes for [18F]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography. J. Med. Chem. 2007, 50:6454-6457.
27. Van Rooijen N., Van Nieuwmegen R. Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol. Commun. 1980, 9:243-256.
28. Wang X., Ishida T., Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 2007, 119:236-244.
29. Zandvoort A., Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol. 2002, 130:4-11.